Multiple myeloma

Malard, Florent; Neri, Paola; Bahlis, Nizar J.; Terpos, Evangelos; Moukalled, Nour; Hungria, Vania T. M.; Manier, Salomon; Mohty, Mohamad

doi:10.1038/s41572-024-00529-7

Nat Rev Dis Primers

2024

DOI: 10.1038/s41572-024-00529-7

|View full text |Cite

Multiple myeloma

Florent Malard,

Paola Neri,

Nizar J. Bahlis

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 281 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Advancements in drugs restructured with nanomedicines for multiple myeloma treatment

Liu,

Shen,

Liu

et al. 2024

Sci. China Mater.

View full text Add to dashboard Cite

Advancements in drugs restructured with nanomedicines for multiple myeloma treatment

Liu,

Shen,

Liu

et al. 2024

Sci. China Mater.

View full text Add to dashboard Cite

Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma

Jeong,

Park,

Young Mo

et al. 2024

Journal of Molecular Biology

View full text Add to dashboard Cite

A roadmap towards improving outcomes in multiple myeloma

Mohty,

Facon,

Malard

et al. 2024

Blood Cancer J.

View full text Add to dashboard Cite

Multiple myeloma (MM) is a chronic hematologic malignancy that remains incurable, because most patients eventually relapse or become refractory to current treatments. MM is a major health problem, with a globally increasing incidence. While, increase in the choice of MM treatment, including new immunotherapies (bispecific monoclonal antibodies and chimeric antigen receptor (CAR)-T cell therapy), may allow to further improve MM patients’ outcomes, some non-therapy-related key issues may represent a pre-requisite towards improving MM outcomes in the next few years. This includes, the necessity of real-world evidence data, of a better definition of frailty, of a dynamic disease risk assessment, of a better definition of high-risk disease, broader accessibility to novel drugs, and to ensure diversity and representation of underrepresented groups. These key issues will be discussed in the current perspective review.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Multiple myeloma

Cited by 3 publications

References 281 publications

Advancements in drugs restructured with nanomedicines for multiple myeloma treatment

Advancements in drugs restructured with nanomedicines for multiple myeloma treatment

Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma

A roadmap towards improving outcomes in multiple myeloma

Contact Info

Product

Resources

About